COVID-19 Management After Recent Exposure in Patients at High Risk of Severe Progression
This protocol applies to individuals who have had recent exposure to COVID-19 and are considered at high risk of progressing to severe disease. The goal is to prevent symptomatic infection before it develops.
Clinical scenario
Recent exposure to COVID-19 in a patient at high risk of progression to severe COVID-19.
Treatment approach
Post-exposure prophylaxis with a specific monoclonal antibody combination may be considered in this setting — but only when predominant regional variants are confirmed susceptible to the agent. The complete eligibility criteria, decision algorithm, and all administration details are contained in the full structured protocol.
Clinical goal
Absence of symptomatic SARS-CoV-2 infection at 28 days.
References
- In persons exposed to COVID-19 who are at high risk of progression to severe COVID-19, the IDSA guideline panel suggests postexposure casirivimab/imdevimab only when predominant regional variants are susceptible to the agent.
- Participants in the treatment group received a total dose of 1200 mg casirivimab/imdevimab subcutaneously.
- Persons receiving PEP with casirivimab/imdevimab reduced symptomatic SARS-CoV-2 infection from 7.8% to 1.5% (RR: .19; 95% CI: .10, .35; moderate CoE).
DOI: 10.1093/cid/ciac724
View source ↗